Table 2.

Duration of symptoms

	<4 wk		4–12 wk		>12 wk		Ongoing
No. of participants with symptoms	242		171		135		104
Fever	159	65.7%	7	4.1%	7	5.2%	7	6.7%
Lymph node swelling	59	24.4%	16	9.4%	12	8.9%	11	10.6%
Loss of taste/smell	167	69.0%	91	53.2%	62	45.9%	50	48.1%
Body aches	205	84.7%	83	48.5%	61	45.2%	54	51.9%
Fatigue	229	94.6%	135	78.9%	91	67.4%	73	70.2%
Sleeping disturbances	135	55.8%	86	50.3%	63	46.7%	56	53.8%
Lack of concentration	135	55.8%	99	57.9%	73	54.1%	60	57.7%
Anxiety	84	34.7%	40	23.4%	28	20.7%	25	24%
Depression	62	25.6%	43	25.1%	31	23.0%	24	23.1%
Headache	203	83.9%	79	46.2%	57	42.2%	47	45.2%
Coryza	175	72.3%	23	13.5%	21	15.6%	19	18.3%
Conjunctivitis	21	8.7%	10	5.8%	10	7.4%	9	8.7%
Otitis	51	21.1%	31	18.1%	28	20.7%	25	24%
Dyspnea	141	58.3%	107	62.6%	73	54.1%	61	58.7%
Sore throat	152	62.8%	28	16.4%	24	17.8%	22	21.2%
Cough	175	72.3%	55	32.2%	31	23.0%	28	26.9%
Angina	106	43.8%	53	31.0%	36	26.7%	29	27.9%
Heart complaints	61	25.2%	47	27.5%	36	26.7%	31	29.8%
Dizziness	125	51.7%	48	28.1%	43	31.9%	36	34.6%
Abdominal pain	53	21.9%	19	11.1%	17	12.6%	16	15.4%
Gastrointestinal complications	94	38.8%	37	21.6%	30	22.2%	26	25%
Nausea	60	24.8%	14	8.2%	10	7.4%	9	8.7%

Related to Figure 1, discovery cohort.